4 minute read | July.10.2023
Shareholders in life science companies made a range of proposals this year, including several related to political activity and public disclosure, access to the COVID-19 vaccine and how patent exclusivity may affect product access.
Orrick’s J.T. Ho, Bobby Bee and Crystal Milo explore key trends in those three categories of proposals in a post for The Corporate Counsel’s Proxy Season blog. They examine shareholder proposals that requested reports on: